CLINUVEL to advance novel pharmaceutical formulations in preclinical program

Core Insights - CLINUVEL is advancing new sustained-release liquid drug formulations in a preclinical program, demonstrating the potential for depot formulations to extend the duration of peptide drug release [1][3] - The company aims to optimize patient exposure to active pharmaceutical ingredients while minimizing dosing through biocompatible formulations that allow flexible dosing based on body weight [2][5] - The preclinical program for the first formulations is expected to complete in the second half of 2026, with an initial focus on melanocortins [3][4] Company Overview - CLINUVEL PHARMACEUTICALS LIMITED is a global specialty pharmaceutical group focused on developing treatments for genetic, metabolic, systemic, and life-threatening disorders [6] - The company is a pioneer in photomedicine and melanocortin peptides, leading to innovative treatments for patients needing systemic photoprotection and other acute conditions [6][7] - CLINUVEL's lead therapy, SCENESSE (afamelanotide 16mg), is approved for commercial distribution in multiple regions as the first systemic photoprotective drug [7]